Toxicity screenings of nanomaterials: Challenges due to interference with assay processes and components of classic in vitro tests

Nanotoxicology

Volumn 9, Issue S1, 2015, Pages 13-24

  Guadagnini, Rina ^a   Halamoda Kenzaoui, Blanka ^b   Walker, Laura ^c   Pojana, Giulio ^d,f   Magdolenova, Zuzana ^e   Bilanicova, Dagmar ^d,f   Saunders, Margaret ^c   Juillerat Jeanneret, Lucienne ^c   Marcomini, Antonio ^d,f   Huk, Anna ^e   Dusinska, Maria ^e   Fjellsbo, Lise M ^e   Marano, Francelyne ^a   Boland, Sonja ^a  

^a UNIVERSITÉ PARIS DESCARTES   (France)

^b UNIVERSITY INSTITUTE OF PATHOLOGY   (Switzerland)

^c ST MICHAEL'S HOSPITAL   (United Kingdom)

^d CA' FOSCARI UNIVERSITY OF VENICE   (Italy)

^e NORWEGIAN INSTITUTE FOR AIR RESEARCH   (Norway)

^f DFBC Department of Phylosophy and Cultural Heritage   (Italy)

Author keywords

Cytotoxicity; Nanomedicine; Nanoparticles; NanoTEST; Oxidative stress; Pro inflammatory response; Testing strategy

Indexed keywords

BROMOBIMANE; DICHLOROFLUORESCEIN; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; INTERLEUKIN 6; INTERLEUKIN 8; LACTATE DEHYDROGENASE; MACROGOL; NANOPARTICLE; NITRIC OXIDE; OLEIC ACID; POLYGLACTIN; PROPIDIUM IODIDE; SILICA NANOPARTICLE; TITANIUM DIOXIDE NANOPARTICLE;

ANIMAL CELL; ARTICLE; CONTROLLED STUDY; CYTOTOXICITY; CYTOTOXICITY ASSAY; ENZYME LINKED IMMUNOSORBENT ASSAY; FIBROBLAST; HUMAN; HUMAN CELL; IN VITRO STUDY; LUNG ALVEOLUS EPITHELIUM CELL; MTT ASSAY; NONHUMAN; OXIDATION; OXIDATIVE STRESS; PRIORITY JOURNAL; RAT; THYMIDINE INCORPORATION ASSAY; TOXICITY TESTING; ZETA POTENTIAL; ANIMAL; CHLOROCEBUS AETHIOPS; PROCEDURES;

ANIMALS; CERCOPITHECUS AETHIOPS; HUMANS; IN VITRO TECHNIQUES; NANOPARTICLES; RATS; TOXICITY TESTS;

EID: 84929993520     PISSN: 17435390     EISSN: 17435404     Source Type: Journal    
DOI: 10.3109/17435390.2013.829590     Document Type: Article

References (30)

1. Aitken RJ, Chaudhry MQ, Boxall AB, Hull M. 2006. Manufacture and use of nanomaterials: current status in the UK and global trends. Occup Med (Lond) 56:300-306.
2. Anders A, James B, Wim DJ, Philippe H, Thomas J, Mats-Olof M, et al. 2009. Risk assessment of products of nanotechnologies. European Commission, Directorate general for health and consumers, Public Health and Risk Assessment. 1-71. Available from: http://ec.euro-pa.eu/health/phrisk/committees/04scenihr/docs/scenihro023.pdf.
3. Barlow S, Chesson A, Collins JD, Flynn A, Hardy A, Jany K-D, et al. 2009. The potential risks arising from nanoscience and nanotechnol-ogies on food and feed safety. EFSA J Eur Comm 958:1-39.
4. Brunauer S, Emmett P, Teller E. 1938. Adsorption of gases in multimolecular layers. J Am Chem Soc 60:10.
5. Correia Carreira S, Walker L, Paul K, Saunders M. 2015. The toxicity, transport and uptake of nanoparticles in the in vitro BeWo b30 placental cell barrier model used within NanoTEST. Nanotoxicology 9(S1):66-78.
6. Cedervall T, Lynch I, Lindman S, Berggård T, Thulin E, Nilsson H, et al. 2007. Understanding the nanoparticle-protein corona using methods to quantify exchange rates and affinities of proteins for nanoparticles. Proc Natl Acad Sci USA 104:2050-2055.
7. Damoiseaux R, George S, Li M, Pokhrel S, Ji Z, France B, et al. 2011. No time to lose-high throughput screening to assess nanomaterial safety. Nanoscale 3:1345-1360.
8. Doak SH, Griffiths SM, Manshian B, Singh N, Williams PM, Brown AP, et al. 2009. Confounding experimental considerations in nanogenotox-icology. Mutagenesis 24:285-293.
9. Griffiths SM, Singh N, Jenkins GJ, Williams PM, Orbaek AW, Barron AR, et al. 2011. Dextran coated ultrafine superparamagnetic iron oxide nanoparticles: compatibility with common fluorometric and colori-metric dyes. Anal Chem 83:3778-3785.
10. Halamoda Kenzaoui B, Chapuis Bernasconi C, Guney-Ayra S, Juillerat-Jeanneret L. 2012. Induction of oxidative stress, lysosome activation and autophagy by nanoparticles in human brain-derived endothelial cells. Biochem J 441:813-821.
11. Han X, Gelein R, Corson N, Wade-Mercer P, Jiang J, Biswas P, et al. 2011. Validation of an LDH assay for assessing nanoparticle toxicity. Toxicology 287:99-104.
12. Juillerat-Jeanneret L, Aguzzi A, Wiestler OD, Darekar P, Janzer RC. 1992. Dexamethasone selectively regulates the activity of enzymatic markers of cerebral endothelial cell lines. In Vitro Cell Dev Biol 28A: 537-543.
13. Kroll A, Pillukat MH, Hahn D, Schnekenburger J. 2009. Current in vitro methods in nanoparticle risk assessment: limitations and challenges. Eur J Pharm Biopharm 72:370-377.
14. Kroll A, Pillukat MH, Hahn D, Schnekenburger J. 2012. Interference of engineered nanoparticles with in vitro toxicity assays. Arch Toxicol 6: 1123-1136.
15. Lundqvist M, Sethson I, Jonsson BH. 2004. Protein adsorption onto silica nanoparticles: conformational changes depend on the particles' curvature and the protein stability. Langmuir 20:10639-10647.
16. Lundqvist M, Stigler J, Cedervall T, Berggård T, Flanagan MB, Lynch I, et al. 2011. The evolution of the protein corona around nanoparticles: a test study. ACS Nano 5:7503-7509.
17. Magdolenova Z, Bilaničová D, Pojana G, Fjellsbø LM, Hudecova A, Hasplova K, et al. 2012. Impact of agglomeration and different dispersions of titanium dioxide nanoparticles on the human related in vitro cytotoxicity and genotoxicity. J Environ Monit 14:455-464.
18. Maynard AD. 2007. Nanotechnology: the next big thing, or much ado about nothing? Ann Occup Hyg 51:1-12.
19. Monteiro-Riviere NA, Inman AO, Zhang LW. 2009. Limitations and relative utility of screening assays to assess engineered nanoparticle toxicity in a human cell line. Toxicol Appl Pharmacol 234:222-235.
20. Oberdörster G, Oberdörster E, Oberdörster J. 2005a. Nanotoxicology: an emerging discipline evolving from studies of ultrafine particles. Environ Health Perspect 113:823-839.
21. Oberdörster G, Maynard A, Donaldson K, Castranova V, Fitzpatrick J, Ausman K, IRFRSINTSW Group. 2005b. Principles for characterizing the potential human health effects from exposure to nanomaterials: elements of a screening strategy. Part Fibre Toxicol 2:8.
22. OECD. 2010. List of manufactured nanomaterials and list of endpoints for phase one of the sponsorship programme for the testing of manufactured nanomaterials: revision. OECD Environ Health Saf Publ Ser Saf Manufactured Nanomaterials 27:1-16.
23. Sanfins E, Dairou J, Hussain S, Busi F, Chaffotte AF, Rodrigues-Lima F, et al. 2011. Carbon black nanoparticles impair acetylation of aromatic amine carcinogens through inactivation of arylamine N-acetyltransfer-ase enzymes. ACS Nano 5:4504-4511.
24. Stone V, Johnston H, Schins RP. 2009. Development of in vitro systems for nanotoxicology: methodological considerations. Crit Rev Toxicol 39:613-626.
25. Turci F, Ghibaudi E, Colonna M, Boscolo B, Fenoglio I, Fubini B. 2010. An integrated approach to the study of the interaction between proteins and nanoparticles. Langmuir 26:8336-8346.
26. Val S, Hussain S, Boland S, Hamel R, Baeza-Squiban A, Marano F. 2009. Carbon black and titanium dioxide nanoparticles induce pro-inflammatory responses in bronchial epithelial cells: need for multiparametric evaluation due to adsorption artifacts. Inhal Toxicol 21(Suppl 1):115-122.
27. Warheit DB, Sayes CM, Reed KL, Swain KA. 2008. Health effects related to nanoparticle exposures: environmental, health and safety considerations for assessing hazards and risks. Pharmacol Ther 120:35-42.
28. Wilhelmi V, Fischer U, van Berlo D, Schulze-Osthoff K, Schins RP, Albrecht C. 2012. Evaluation of apoptosis induced by nanoparticles and fine particles in RAW 264.7 macrophages: facts and artefacts. Toxicol In Vitro 26:323-334.
29. Wörle-Knirsch JM, Pulskamp K, Krug HF. 2006. Oops they did it again! Carbon nanotubes hoax scientists in viability assays. Nano Lett 6: 1261-1268.
30. Xu Z, Liu XW, Ma YS, Gao HW. 2010. Interaction of nano-TiO2 with lysozyme: insights into the enzyme toxicity of nanosized particles. Environ Sci Pollut Res Int 17:798-806.